A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis

Multiple Sclerosis : Clinical and Laboratory Research
M GironiG Martino

Abstract

A sixth month phase II multicenter-pilot trial with a low dose of the opiate antagonist Naltrexone (LDN) has been carried out in 40 patients with primary progressive multiple sclerosis (PPMS). The primary end points were safety and tolerability. Secondary outcomes were efficacy on spasticity, pain, fatigue, depression, and quality of life. Clinical and biochemical evaluations were serially performed. Protein concentration of beta-endorphins (BE) and mRNA levels and allelic variants of the mu-opiod receptor gene (OPRM1) were analyzed. Five dropouts and two major adverse events occurred. The remaining adverse events did not interfere with daily living. Neurological disability progressed in only one patient. A significant reduction of spasticity was measured at the end of the trial. BE concentration increased during the trial, but no association was found between OPRM1 variants and improvement of spasticity. Our data clearly indicate that LDN is safe and well tolerated in patients with PPMS.

Associated Clinical Trials

References

Feb 1, 1989·Neurosurgery·D L EricksonM Michaelson
Feb 1, 1987·Physical Therapy·R W Bohannon, M B Smith
Jul 1, 1982·Medicinal Research Reviews·M S GoldM P Dackis
Jul 31, 1998·Nature·A CalignanoD Piomelli
Jul 3, 1999·Trends in Pharmacological Sciences·J ManzanaresJ A Fuentes
Mar 18, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·M GironiP Sacerdote
Apr 1, 2003·Expert Opinion on Investigational Drugs·David Baker, Gareth Pryce
Jun 19, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·David W OslinCharles P O'Brien
Aug 2, 2003·Nature Medicine·Christoph SteinHalina Machelska
Aug 30, 2003·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·S A PageJ C Levy
Jun 1, 1961·Archives of General Psychiatry·A T BECKJ ERBAUGH
Oct 9, 2003·Biological Research for Nursing·Natalie Ann Rasmussen, Lynne A Farr
Jan 7, 2004·Life Sciences·Diana L Cichewicz
Jun 29, 2004·Multiple Sclerosis : Clinical and Laboratory Research·George C Ebers
Feb 12, 2005·Proceedings of the National Academy of Sciences of the United States of America·Mohab M IbrahimT Philip Malan
Jun 2, 2005·Pharmacology, Biochemistry, and Behavior·Daniela ViganòDaniela Parolaro
Nov 12, 2005·Annals of Neurology·Chris H PolmanJerry S Wolinsky
Jul 13, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M PugliattiI Milanov
Jan 16, 2007·The American Journal of Gastroenterology·Jill P SmithIan S Zagon
May 15, 2007·Current Opinion in Neurology·Sandra Vukusic, Christian Confavreux
Jan 23, 2008·Expert Opinion on Therapeutic Targets·Fabian DocagneCarmen Guaza

❮ Previous
Next ❯

Citations

Jan 1, 2013·Investigational New Drugs·Moshe RogosnitzkyIan S Zagon
Jun 6, 2012·Cell Research·Changsheng Du, Xin Xie
Mar 12, 2013·Antioxidants & Redox Signaling·Djordje Miljković, Ivan Spasojević
Sep 16, 2011·International Journal of Rheumatology·Tracy FrechAllen D Sawitzke
May 21, 2009·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Jarred Younger, Sean Mackey
Mar 29, 2011·Neurologic Clinics·Allen C Bowling
Oct 2, 2009·Peptides·Richard J Bodnar
Dec 2, 2008·Medical Hypotheses·Norman Brown, Jaak Panksepp
Aug 10, 2010·Annals of Neurology·Bruce A C CreeDouglas S Goodin
Mar 17, 2015·Lancet Neurology·Anthony FeinsteinAlbert C Lo
Jun 11, 2010·Multiple Sclerosis : Clinical and Laboratory Research·Naser SharafaddinzadehBita Shalbafan
Apr 22, 2011·Journal of Pharmacy Practice·Soheyla MahdavianAngela Hill
Jun 14, 2017·Multiple Sclerosis Journal - Experimental, Translational and Clinical·Michael D LudwigPatricia J McLaughlin
May 11, 2011·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Guttorm Raknes, Trude Giverhaug
Oct 1, 2010·Continuum : Lifelong Learning in Neurology·Allen C Bowling
Jun 5, 2016·Continuum : Lifelong Learning in Neurology·Patricia K Coyle
Jul 24, 2015·Journal of Clinical Psychopharmacology·Anthony P TurelPatricia J McLaughlin
Sep 27, 2018·Medical Sciences : Open Access Journal·Karlo Toljan, Bruce Vrooman
Jan 24, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Claire MazaheryAlan D Levine
Jun 27, 2014·Pain Medicine : the Official Journal of the American Academy of Pain Medicine·Babita GhaiChirag Shashikant Shah
Aug 28, 2020·Current Pain and Headache Reports·Phillip S Kim, Michael A Fishman
Jun 21, 2011·Experimental Biology and Medicine·Renee N DonahueIan S Zagon
Aug 3, 2017·Experimental Biology and Medicine·Michael D LudwigPatricia J McLaughlin
Aug 25, 2021·International Immunopharmacology·Hai HuangFengping Shan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.